TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* participants \>/= 18 years of age~* patients for whom POC testing would change their course of treatment (in opinion of treatment team)~Exclusion Criteria:~* patients in whom conventional COVID-19 testing would not have otherwise been performed~* patients in whom immediate COVID-19 testing would not alter short-term treatment~* patients who refuse consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients consulted upon by ICU, internal medicine, or cardiology for hospital admission (Type: EXPERIMENTAL): All patients will have both standard care and point-of-care (experimental) NP swabs performed.
- patients undergoing cardiac testing/procedures (Type: EXPERIMENTAL): All patients will have both standard care and point-of-care (experimental) NP swabs performed.
- patients awaiting surgery (Type: EXPERIMENTAL): All patients will have both standard care and point-of-care (experimental) NP swabs performed.
- Health Care Workers (Type: EXPERIMENTAL): Health Care Workers who are being screened for COVID-19 will have both standard care and point-of-care NP swabs performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of obesity~* diagnosed ORG by renal biopsy~* LDL\>3.37mmol/L~* Proteinuria 0.5-3.5g/d~* eGFR (CKD-EPI formula) \> 30ml/min~Exclusion Criteria:~* Other concomitant renal diseases~* Endocrine or drug-induced obesity;~* Type 2 diabetes~* eyes or obvious microscopic hematuria;~* Swallowing difficulty / severe gastrointestinal dysfunction~* intestinal obstruction;~* severe arrhythmia;~* Hypophosphatemia (\<0.7mmol/L);~* allergic to Sevelamer Carbonate~* unable to well cooperate~* Females who are in the period of gestation or lactation, or refuse to use contraception;~* participated in other clinical trial of drug within three months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A Group (Type: EXPERIMENTAL): None
- B Group (Type: EXPERIMENTAL): None
- C Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Men and women with type 2 diabetes that will need enteral nutrition with carbohydrate content.~* Glycemia \>140mg/dL and \< 400mg/dL at admission on the ward.~* Informed consent (patient or legally authorized representative)~Exclusion criteria:~* Hypersensibility to insulin glargine or glulisine, or any other component of the insulin formulation.~* Use of investigational medications during the last 12 months or use of any investigational insulin preparation during the last 4 months.~* History of diabetic ketoacidosis or hyperosmolar hyperglycaemic state or ketonuria.~* Subjects with conditions that are expected to need surgery or intensive care unit (ICU)admission based on discussions with the treatment team and attending physician.~* Pregnancy.~* Severe hepatic disease or active hepatitis.~* Cardiac failure class III or IV (Classification de la New York Heart Association:NYHA).~* Diagnosed advanced autonomic neuropathy.~* Diagnosed cancer.~* Active infection.~* Current therapy with steroids.~* Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Insulin Glargine + Insulin Glulisine
- 2 (Type: ACTIVE_COMPARATOR): Insulin Glulisine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Edwards SAPIEN-3 Periprosthetic Leakage Evaluation Versus Medtronic CoreValve in Transfemoral Aortic Valve Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~In order to be eligible to participate in this study, subjects must meet all of the following criteria:~* Patient is ≥18 years of age and diagnosed with severe symptomatic aortic stenosis, judged inoperable or at high surgical risk (EuroSCORE \> 15% or other criteria that make surgery high risk by a consensus among cardiologists and cardiac surgeons in the heart team) and deemed eligible for transfemoral-TAVI.~* Aortic annulus diameter ≥ 18 and ≤ 29 mm as assessed with MSCT.~* No contraindications to study requirements such as MRI or TEE.~Exclusion criteria~* Patients unable or unwilling to give informed consent.~* Patients who are excluded from this study because of the size of their aortic annulus diameter.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edwards SAPIEN bioprosthesis (Type: ACTIVE_COMPARATOR): Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
- Medtronic CoreValve® system (Type: ACTIVE_COMPARATOR): Transcatheter aortic valve replacement with the Medtronic CoreValve system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electrocardiographic Modifications and Spontaneous Hypoglycemic Episodes in Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years old;~* Be able to give informed consent;~* Diagnosis of type 1 diabetes for ≥ 6 months;~* Treated with intensive insulin therapy (multiple injections of insulin or insulin pump)~AND EITHER~* A history of CV disease defined as: 1) Established diagnosis of atherosclerotic coronary artery disease (example: previous history of infarction); 2) Previous cerebral Vascular Stroke or Transient Ischemic Accident; 3) Anterior revascularization of the coronary arteries, carotid artery or peripheral arteries; 4) At least one coronary stenosis, carotid artery or lower extremity arteries \> 50%; 5) History of symptomatic coronary heart disease confirmed with hospitalization or a positive stress test result or by any cardiac imaging result, or unstable angina with changes observed at the ECG; 6) Asymptomatic cardiac ischemia confirmed by a nuclear imaging test, an exercise test, a dobutamine stress echo; 7) NYHA II-III class chronic heart failure; 8) Amputation of limb or foot due to circulatory insufficiency.~* Or more than 20 years duration of T1D and at least 2 of the following risk factors or associated condition: 1) Chronic renal failure eGFR \<60 ml / min / 1.73 m2); 2) Presence of micro or macro-albuminuria (albumin / creatinine ratio \> 2); 3) Hypertension or treatment for hypertension; 4) Hyperlipidemia or treatment for hypolipemia; 5) Abdominal obesity (Waist circumference\> 94 cm for men and \> 80 cm for women); 6) Smoking ; 7) Significant retinopathy (pre-proliferative, proliferating, laser or intravitreous injection); 8) Body mass index \> 30 kg /m2; 9) Erectile dysfunction; 10) Left ventricular hypertrophy; 11) Positive family history of early MCAS (H \< 55 years old and F \< 65 years old)~Exclusion Criteria:~* Definitive criteria: 1) QRS \> 120 ms on the baseline ECG; 2) Presence of atrial fibrillation at inclusion; 3) Current intake of any drug that may prolong QT according to the judgment of the investigator and the update of the list available on www.professionsante.com.~* Transient criteria (the patient can be included once the anomaly is corrected): 1) Hypokalemia (\< 3.5 mmol/L); 2) Hypocalcemia (ionized calcium \< 1.10 mmol/L); 3) Hypomagnesemia (\< 0.7 mmol/L)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with type 1 diabetes with a high cardiovascular risk (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Study to Assess Betadine in the Groin Wound of Patients Undergoing Primary Varicose Vein Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing primary saphenofemoral ligation for varicose veins (can be combined with short saphenous surgery).~Exclusion Criteria:~* Allergy to iodine~* Redo groin dissections~* Patients having multiple avulsions only or saphenopopliteal ligation only~* Patients unable to return to outpatients for 6 weeks to undergo assessment with the wound care nurse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Betadine (Type: EXPERIMENTAL): None
- Saline (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory critical limb ischemia (Rutherford Score 4/5)~* Not optimal for surgical or catheter-based revascularization~* Obstructive atherosclerosis of at least 1 major artery in both limbs~* Ankle-Brachial Index \<0.6 or Absolute Ankle pressure \<60mmHg or toe pressure \<40mmHg or pulse volume recording that is flat or barely pulsatile~Exclusion Criteria:~* Gangrene(Rutherford 6) or pre-existing major tissue loss~* Unstable Angina, MI, stroke, CHF (class III or IV) within 6 months of study treatment

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Autologous Stem cells (CD133+) (Type: ACTIVE_COMPARATOR): Intramuscular injection
- Control (Type: PLACEBO_COMPARATOR): Intramuscular Injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with newly diagnosed, advanced nonsquamous NSCLC referred to the Cleveland Clinic Taussig Cancer Center from outside centers without prior testing results available for targetable genetic alterations~* Plan to receive systemic therapy at the Cleveland Clinic, OR plan to receive systemic therapy at an outside site while maintaining either intermittent follow up at Cleveland Clinic or with electronic health record access through Care Everywhere.~Exclusion Criteria:~* Prior therapy for this diagnosis of NSCLC~* Prior adequate molecular testing done for the current diagnosis of NSCLC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liquid biopsy (Type: EXPERIMENTAL): A liquid biopsy is a test will be done on a sample of blood to look for cancer cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older~* Receiving intravenous vancomycin for the treatment of healthcare associated pneumonia, osteomyelitis/septic arthritis, endocarditis/bacteremia, or acute bacterial skin and skin structure infections~* Expected to receive vancomycin for at least 72 hours and are within the first 72 hours of therapy~* Have at least two or more of the following risk factors for drug-induced nephrotoxicity: a) receipt high-dose vancomycin therapy (greater than or equal to four grams per day) b) receipt of vasopressors c) receipt of nephrotoxic drugs (i.e. aminoglycosides, furosemide, acyclovir, amphotericin b, colistin, and intravenous contrast dye) d) pre-existing renal dysfunction (i.e. SCr greater than or equal to 1.5 mg/dL).~Exclusion Criteria:~* Pregnancy~* End-stage renal disease~* Receipt of more than 4 grams of vancomycin prior to enrollment on current admission~* Absolute neutrophil count \< 1000/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin (Type: ACTIVE_COMPARATOR): None
- Comparator (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Labor Epidurals for Postpartum Tubal Ligation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women~* 18 to 45 years of age~* Admitted to MUSC in labor or for induction of labor resulting in a vaginal delivery epidural analgesia~* Postpartum tubal ligation following delivery~* American Society of Anesthesiologists (ASA) Physical Class 1, 2, and 3~Exclusion Criteria:~* Critically Ill Patients (patients admitted to the ICU)~* Cognitively Impaired Persons (patients with a diagnosis of cognitive deficit)~* Cesarean delivery~* Punctured dura~* Patients enrolled in other epidural research studies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Capped Epidural (Type: ACTIVE_COMPARATOR): Group 1 (control) will have the epidural catheter capped and left in place.
- Normal Saline Infusion (Type: EXPERIMENTAL): Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Beneficial Effects of Exercise and Healthy Diets on Muscle and Adipose Tissue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~CROSS SECTIONAL: male sex, age 25 -50 years, with BMI ranging from 20 to 35 kg/mt2. INTERVENTION STUDY: Overweight or obese men and women aged 25 - 50 years interested in losing weight,will~Exclusion Criteria:~CROSS SECTIONAL : diabetes mellitus, chronic neuromuscular or neurological deficits precluding normal physical activity, heavy smoking (\> 5 cigarettes per day), alcohol intake \> 30 g/day and chronic diseases such as cancer, HIV-AIDS, renal, pulmonary, cardiac or hepatic conditions.~INTERVENTION STUDY: weight fluctuations (\> 3 k in the last 3 months), diabetes mellitus, chronic neuromuscular or neurologic diseases, heavy smoking (\> 5 cigarettes per day) and alcohol intake \> 30 g/day, and chronic diseases such as cancer, HIV, renal, pulmonary, cardiac or hepatic conditions.~-

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- control period (Type: SHAM_COMPARATOR): control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
- Diet group (Type: EXPERIMENTAL): Mediterranean diet prescription during 3 months
- Exercise group (Type: EXPERIMENTAL): Subjects will be trained 3 times a week during 3 months
- Diet + Exercise (Type: EXPERIMENTAL): Both a dietary prescription plus exercise training during 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Angiotensin Inhibitors During the Perioperative Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic ACEI or ARB use for the treatment of hypertension. Patients who use a com-bination pill with a diuretic are eligible as well;~* Scheduled for elective intermediate to high risk noncardiac surgery, defined according to the European Society of Cardiology / European Society of Anesthesiology guidelines on noncardiac surgery;~* Expected postoperative length of stay of at least two days.~Exclusion Criteria:~* Severe chronic kidney disease, defined as GFR\<30 ml/min/1.73 m2;~* ACEI/ARB use for the treatment of chronic systolic heart failure, defined as left ven-tricular ejection fraction ≤40%;~* ACEI/ARB use within one year after ST-elevated myocardial infarction, according to the fourth universal definition of myocardial infarction;~* Transplant surgery;~* ACEI/ARB use in a combination pill together with a drug other than a diuretic, including calcium channel blockers, beta-blockers and neprilysin inhibitors;~* Use of drugs acting on the renin-angiotensin-aldosterone system other than ACEI/ARB, e.g. aliskiren.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Perioperative withdrawal of ACEI/ARB.
- Control group (Type: ACTIVE_COMPARATOR): Perioperative continuation of ACEI/ARB.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gingival Augmentation and Root Coverage With Superficial and Deep Cut Acellular Dermal Matrices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between age 18 and 89~* Patients needing root coverage procedures for gingival recession in one or more teeth in the same arch bilaterally (split mouth)~* Patients must be nonsmokers, former smokers, or current smokers who smoke \<10 cigarettes per day, by self-report.~* Female patients who have undergone a hysterectomy, tubal ligation, or menopause, and non- pregnant women of child-bearing potential.~Exclusion Criteria:~* Patients who disclose that they will not be able to cooperate with the follow-up schedule.~* Patients who are mentally incompetent, prisoners, or pregnant (as obtained via chart review or self-report)~* Pregnant women or women intending to become pregnant during study period.~* Smokers who smoke \> 10 cigarettes per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Control Group: Acellular Dermal Matrix - Superficial cut (ADM-S) (Type: PLACEBO_COMPARATOR): A commonly used allograft material is the Acellular Dermal Matrix (ADM) which is harvested from human donor dermal tissues. Most commercially available ADM products are superficial cuts.
- Test Group:Acellular Dermal Matrix - Deep cut (ADM-D) (Type: ACTIVE_COMPARATOR): The use of a deep cut ADM for root coverage gingival plastic procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues